NCT01685255View on ClinicalTrials.gov

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 23, 2014

Study Completion Date

October 23, 2014

Conditions
Ovarian CancerGenitourinary (GU) Tumors
Interventions
DRUG

Epacadostat

DRUG

tamoxifen

Trial Locations (49)

Unknown

La Jolla

Los Angeles

San Francisco

Evanston

Joliet

Iowa City

Covington

Baltimore

Detroit

Minneapolis

Bridgewater

Buffalo

Mineola

Durham

Abington

Philadelphia

Greenville

Bendigo

Heidelberg

Herston

Milton

Randwick

Calgary

Toronto

Montreal

Izhevsk

Krasnodar

Kursk

Moscow

Orenburg

Saint Petersburg

Ufa

Yekaterinburg

Chernivtsi

Dnipro

Kharkiv

Lutsk

Bebington

Cardiff

Edinburgh

Glasgow

Keighley

Leeds

Liverpool

London

Manchester

Nottingham

Oxford

West Midlands

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT01685255 - A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | Biotech Hunter | Biotech Hunter